Sharing is caring!

Daiichi Sankyo announced that it has strategically partnered with Ultragenyx for unrestricted use of Ultragenyx’s proprietary adeno associated virus (AAV) based gene therapy manufacturing technology.

At present, Daiichi Sankyo is doing investigations for gene therapy drugs using AAV vectors, and to deliver gene therapy drugs to patients in the future, it is crucial to also form in-house manufacturing technology initially.

In this partnership, Daiichi Sankyo will accomplish a technology transfer from Ultragenyx and afterward, Daiichi Sankyo will expand its manufacturing capacity with the cooperation of Ultragenyx and start the manufacture of investigational drugs for AAV gene therapy by the mid-2020s.

Daiichi Sankyo has pledged to generate next-generation drugs, including focused modalities such as gene therapy, nucleic acid medicines, and cell therapy, toward sustained growth beyond achieving its 2025 Vision and in line with the company’s goal of becoming a “Global Pharma Innovator with Competitive Advantage in Oncology”.

(Source: Daiichi Sankyo, 2020)